Sihuan Pharma entered a three-year collaboration with RaQualia Pharma of Japan to develop novel drug candidates for pain relief. The two companies will employ multiple lead-discovery technologies, including high-throughput screening technology, to identify promising candidates for a specific ion channel target. Sihuan will own greater China rights to any products developed by the collaboration, and RaQualia will share in ex-China profits. Sihuan will carry out the work through its Shandong XuanZhu Pharma subsidiary.
